Legacy in Motion: Why the LMI Advance Brain Study Matters
At Be Well Clinical Studies, our mission is to contribute to the future of medicine through research that’s both scientifically rigorous and ethically grounded. Among the many studies we are proud to lead, the LMI Advance Brain Study stands out for both its clinical significance and its human impact.
A Study with Transformative Potential
This end-of-life study, sponsored by Life Molecular Imaging, is designed for individuals aged 50 or older with a life expectancy of 12 months or less, with or without a dementia diagnosis. Its purpose is to evaluate whether a PET scan tracer can detect tau protein: a key biomarker associated with Alzheimer’s disease, with accuracy comparable to a post-mortem brain autopsy.
According to Dr. AJ Ryan, lead investigator on the study, the potential impact is profound:
“At this point, medically, we have nothing to objectively give us a diagnosis of Alzheimer's until someone starts to show symptoms. By that point, the disease is already impacting daily life. If we have a radiotracer to detect this disease years earlier, we can start to slow the progression long before patients have symptoms.”
This study represents a rare opportunity to validate imaging technology against actual brain tissue. If successful, the findings could accelerate early diagnosis and allow for more timely, targeted interventions—potentially giving individuals more good years of life.
Designed with Care, Executed with Precision
Participation in this study involves just two clinical visits—one for a medical evaluation, and one for the PET scan—and is supported by ongoing communication and logistical coordination. Be Well works closely with caregivers, hospice providers, and local pathologists to ensure the process is not only efficient but handled with dignity and care.
Brain tissue is collected after death and sent to a central lab, while the body is returned to the family in accordance with their wishes. Our team ensures this is not simply a process—it is a deeply respectful exchange rooted in transparency and gratitude.
A Meaningful Contribution to Medical Advancement
Alzheimer’s is a disease for which we currently have no cure. However, we do have treatments that may slow its progression—especially when initiated early. That’s why research like this is so critical. The LMI Advance Brain Study could provide the data needed to bring us closer to earlier detection, better treatment planning, and improved outcomes.
Importantly, because this is a relatively small study, each volunteer enrolled has an outsized impact. Their contribution is not symbolic—it’s scientifically significant.
If you or a loved one may qualify, or if you work with patients in hospice or palliative care, fill out our contact form to have a member of our team reach out. Our team will walk you through the details respectfully and without pressure.
This is legacy in motion. And we are honored to be part of it.